

**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 28-3-2008

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 09-2-2008 TO BE PUBLISHED ON 29-3-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

104/2008	04-02-2008 Boehringer Ingelheim International GmbH. Germany. (Priority 06-02-07 Europe)	“Process”
105/2008	Wyeth. USA. (Priority 05-02-07 USA)	“Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator-1 (PAI-1)”
106/2008	Wyeth. USA. (Priority 05-02-07 USA)	“Novel indole poly morphs”
107/2008	AstraZeneca AB. Sweden. (Priority 09-02-07 USA)	“Pharmaceutical compositions -659”
108/2008	AstraZeneca AB. Sweden. (Priority 12-02-07 USA)	“Chemical compounds”
109/2008	Columbia Laboratories (Bermuda) Limited. Bermuda. (Priority 06-02-07 USA)	“Progesterone for the treatment or prevention of spontaneous preterm birth”
110/2008	DyStar Textilfarben GmbH & Co. Germany. (Priority 06-2-07 Germany)	“Mixtures of fiber-reactive azo dyes”
111/2008	SmithKline Beecham Corporation. USA. (Priority 07-02-07 USA)	“Inhibitors of AKT activity”
112/2008	06-02-2008 Novartis AG. Switzerland. (Priority 09-02-07 Europe).	“Organic compounds”
113/2008	Takeda Pharmaceutical Company Limited. Japan. (Priority 09-02-07 Japan).	“Fused ring compound”
114/2008	07-02-2008 BASF SE. Germany. (Priority 09-02-07 USA)	“Liquid pesticide concentrate formulation comprising phenylsemicarbazone compounds”
115/2008	Laboratorios Almirall, S.A. Spain. (Priority 09-02-2007 Spain)	“Napadisylate salt of 5-(2-([6-(2,2-difluoro-2-phenylethoxy)hexyl]amino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the (Beta 2) adrenergic receptor”

116/2008	AstraZeneca AB. Sweden. (Priority 08-02-07 GB)	“Salts 668”
117/2008	Dollar Industries Pakistan Karachi-Pakistan.	“An improved ink filling system for a pen”
118/2008	Daiichi Sankyo Company Ltd. Japan. (Priority 08-02-2007 USA)	“Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof”
119/2008	08-02-2008 Industrie De Nora S.P.A. Italy. (Priority 22-02-07 USA)	“Catalyst for electrochemical reduction of oxygen”
120/2008	Eisai London Research Laboratories Limited. United Kingdom.	“7-azaindole derivatives and their use in the inhibition of C-jun N-terminal kinase”
121/2008	Ortloff Engineers, Ltd. USA. (Priority 09-02-2007 USA)	“Hydrocarbon gas processing “
122/2008	IRM LLC. Bermuda. (Priority 09-02-2007 USA)	“Compounds and compositions as channel activating protease inhibitors”
123/2008	Do mantis Limited. United Kingdom. (Priority 08-02-2007 USA)	“Ligand”
124/2008	09-2-2008 Cool Energy Limited, Australia (Priority 09-2-07 Australia)	“Process and apparatus for depleting carbon dioxide content in a natural gas feedstream containing ethane and C3+hydrocarbons”
125/2008	1.Dr.M. Riaz, 2.Nazir Jan, 3.Farid Ullah Khan and 4.Mu mtaz Khan PCSIR, Laboratories Peshawar, Pakistan	“Preparation of calcium carbonate (B.P Grade)”
126/2008	1.Dr. Abdur Rahman Khan 2.Mu mtaz Khan, and 3.Muhammad Tahseen Aslam, PCSIR, Laboratories Peshawar, Pakistan	“A process for the treatment of wastewater of automobile service stations and its recycling”
127/2008	Vestergaard Frandsen SA Switzerland (Priority 13-2-07 Denmark)	“Process and composition for synergistically enhanced insecticidal impregnation of fabric or netting or other kind of non-living material”
128/2008	E.I. DU Pont Nemours and Company, USA (Priority 08-3-07 US)	“Liquid sulfonylurea herbicide formulations”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

310/1996	F. Hoffman-La Roche AG, Switzerland	“A unit dose pharmaceutical composition which increase the bioavailability of proteinase inhibitor” (INT.CL. A61K 31/47)	139377
		Compositions which increase the bioavailability of proteinase inhibitors are disclosed. The compositions include a pharmaceutically acceptable carrier comprising monoglycerides of medium chain-fatty acids.	
489/1996	Bayer Aktiengesellschaft Germany	“Pesticidal composition comprising β -cyfluthrin” (A01N, 53/02)	139378
		New pesticidal compositions which comprise At least one signal substance, At least one UV absorber which is only sparingly miscible with water, At least one unsaturated oil which is only sparingly miscible with water and, if desired, pesticidally active compounds and/or additives, and their use for controlling insects and undesirable representatives of the order Acarina.	

472/1997 UCB, S. A.
Belgium

“A pharmaceutical composition comprising a combination of hydroxyzine and a serotonin uptake inhibitor”

(A61K, 31/02, P25/00)

139 379

The present invention relate to a pharmaceutical composition comprising (i) hydroxyzine, and individual optical isomer thereof and (iii) at least one therapeutic substance which is a serotonin uptake inhibitor, an optical isomer thereof, which may be used in the treatment of depressive disorders, which lacks the negative effects observed when a combination of said therapeutic substance (ii) and benzodiazepines is used.

529/1997 Wyeth Holdings
Corporation.
USA

“Tricyclic benzazepine vasopressin antagonist”

(C07D 223/16, A61K 31/55)

139380

This invention relates to new tricyclic Benzazepine non-peptide vasopressin antagonists which are useful in treating conditions where decreased vasopressin levels are desired, such as in congestive heart failure, in disease conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction.


942/1998 Boehringer Ingelheim
Pharma GmbH & Co.
KG.
Germany.

“1, 2, 3, 4, 5, 6-hexahydro-2, 6-methano-3-benzazocin-10-oles.”

(Co7D, 489/00)

139381

The present application relates to new, substituted 1, 2, 3, 4, 5, 6-hexahydro-2, 6-methano-3-benzazocin-10-ols of general formula 1.



1223/1998 Athena NeuroSciences, Inc.
USA

“ A pharmaceutical composition comprising an agent effective to induce an immunogenic response against A β in a patient”

(C08B, 33/00)

139382

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A β peptide or an antibody thereto.

223/1999 Eli Lilly and Company,
USA

“2-methyl-thieno-benzodiazepine formulation”

(C07D, 223/16)

139383

The present invention provides a composition comprising olanzapine and an oleaginous or cholesterol microsphere carrier. Which is useful in preparing sustained release composition in the release rate is minimally dependent on the pH of the environment.

647/1999 Zeneca Limited,
England

“BASE-Triggered release microcapsule”

(A01N, 25/28)

139384

Microcapsules formed from an aminoplast shell wall and an encapsulated ingredient or ingredients enclosed within the wall in which the wall contains a base-cleavable ester moiety.

These capsules have been found to be sensitive to the presence of base such that in the presence of base, the capsule walls are relatively quickly disintegrated or degraded so as to produce a relatively quick release of the encapsulated materials.

Microcapsules of this invention are particularly suitable for use in controlling insects having an alkaline gut such as certain lepidoptera in that the capsule shell wall may be designed so as to quickly disintegrate under the alkaline conditions present in the gut of the insect thus providing a microcapsule which is safe to handle but which is selectively effective against certain undesirable insects while not harmful to beneficial insects or insects which do not feed on the capsule materials.

108/2000 1.Syngenta Limited
United Kingdom
2. Shionogi & Co. Ltd.
Japan

“A non-interacting composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methylsulfonyl]amino]pyrimidin-5-yl](3R, 5S)-3,5-dihydroxyhept-6-enoic acid”

(A61K 31/505)

139385

The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the agent) and a drug which is either an inducer, inhibitor or substrate of cytochrome p450, in particular cytochrome p450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments.


641/2000 F. Hoffmann-La Roche
AG,
Switzerland

“Vitamin D3”

(Co7C 401/00)

139386

Compounds of the formula




Wherein

R1 is hydrogen or an alkyl group;

R2 is hydrogen or an alkyl group; or

R1, R2 and C20 together are cyclopropyl;



R3 is alkyl, hydroxy-alkyl or fluoroalkyl; and
 R4 is alkyl, hydroxy-alkyl or fluoroalkyl
 Which are useful in the treatment of breast cancer, prostate cancer, prostate cancer, myeloid leukemia benign prostate growth, baldness and osteoporosis?

1129/2000 Novartis AG,
 Switzerland

“A pharmaceutical composition comprising tegaserod and omeprazole”

(A61K 31/13)

139387

The present invention concerns a pharmaceutical composition comprising a. tegaserod and b. omeprazole enantiomer or racemate thereof, and its use as a medicament, particularly in the treatment of gastrointestinal disorders such as gastro-esophageal reflux disease (GERD).


101/2001 Merck Patent GmbH
 Germany

“Compound of 5-Arylnicotinaldehyde”

(Co7D 213/48)

139388

A compound of 5-arylnicotinaldehydes of the formula 1.



In which

A is a phenyl radical or naphthyl radical, each of which is unsubstituted or monosubstituted or polysubstituted by R, F, Cl, Br, I, -CN, -NO₂, -CF₃, -OCF₃, -OCF₂CF₃ -OCHF₂CF₃ or -OH and which, in addition, one or more CH groups may be replaced by N,

897/2001 Glaxo Group Limited,
United Kingdom

“A vaccine composition comprising a 1H-imidazo[4,5-C]quinolin-4-amine”

(A61K 39/39)

139389

The present invention relates to the use of a 1H-imidazo [4,5-C] quinolin-4-amine as an adjuvant for use with nucleic acid vaccination.


1213/2001 Daiichi Pharmaceutical
Co, Ltd.
Japan

“Aryl/cycloalkyl-carboxylic acid”


(Co7D 263/16)

139390

The present invention relates to a compound represented by the following formula (I):



{wherein, W represents $\text{W}^{\text{A}}-\text{A}^1-\text{W}^{\text{B}}$ (in which, W^{A} is substituted or unsubstituted aryl, etc., A^1 is $-\text{NR}^1$ -, single bond, $-\text{C}(0)$ -, etc., and W^{B} is substituted or unsubstituted arylene, etc.), R is single bond, $-\text{NH}$ -, $-\text{OCH}_2$ -, alkenylene, etc., X is $-\text{C}(0)$ -, $-\text{CH}_2$ ~, etc., and M is, for example, the following formula:



(in which, R^{11} , R^{12} and R^{13} each independently represents hydrogen, hydroxyl, amino, halogen, etc., R^{14} is hydrogen or lower alkyl, Y represents $-\text{CH}_2\text{O}$ -, etc., Z is substituted or unsubstituted arylene, etc., A^2 is single bond, etc., and R^{10} is hydroxyl or lower alkoxy)], or salt thereof; and a pharmaceutical containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.


101/2002 AstraZeneca AB
Sweden.

“Pyrimidine compound”

(CO7D 487/04, A61P 35/00)

139391

Compound of the formula (I):



(I)

(Wherein Ring A, R^1 , R^3 , R^4 , p, q, and n are as defined within and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

191/2002 AstraZeneca AB.
Sweden.

“Novel hydantion “

(Co7D 233/72,)

139392

Compound of the formula (I):



Wherein z is SO_2 or SO , useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.


434/2002 Pfizer Products Inc.
USA.

“Crystal form of azithromycin”

(Co7G 11/00)

139393

This invention relates to crystal forms of azithromycin. Azithromycin is sold commercially and is an effective antibiotic in the treatment of a broad range of bacterial infections. The crystal forms of this invention are likewise useful as antibiotic agents in mammals, including man, as well as in fish and birds. Azithromycin has the following structural formula:



458/2002	Saechsisches Serumwerk Dresden Branch of SmithKline Beecham Pharma GmbH & Co. KG. Germany.	<p>“A composition comprising stable inactive influenza vaccine.”</p> <p>(C12N 7/04)</p>	139394
		<p>An inactivated influenza virus composition is described which comprises a haemagglutinin antigen stabilized in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin is detectable by a SRD assay. The influenza virus composition may comprise a micelle modifying excipients, for example α tocopherol in a sufficient amount to stabilize the haemagglutinin.</p>	
463/2002	Eli Lilly and Company USA.	<p>“A stable crystalline salt of 1-(indole-6-carbonyl-d-phenylglyciny)-4-(1-methylpiperidin-4-yl) piperazine difumarate”</p> <p>(Co7D 295/04)</p>	139395
		<p>1-(Indole-6-carbonyl-D-phenylglyciny)-4-(1-methylpiperidin-4-yl) piperazine Difumarate and is an inhibitor of the serine protease, Factor Xa, useful in the treatment of cardiovascular disorders.</p>	
557/2002	Aventis Pharma S.A. France.	<p>“Pharmaceutical composition comprising a cellulosic polymer,</p> <p>(A61K 9/16)</p>	139396
		<p>The invention relates to a pharmaceutical formulation in powder form intended for oral administration in an aqueous suspension, having a masked taste, comprising at least a cellulosic polymer, a methacrylic polymer and an active ingredient distributed homogeneously and in the molecular state in an atomized matrix, as well as an alkaline agent and an adsorbent agent, a process for its preparation and a method for masking the taste of pharmaceutical products</p>	

663/2002 F. Hoffmann-La Roche
AG.
Switzerland.

“2-(3, 5-Bis-trifluoromethyl-phenyl)-N-[6-(1, 1-dioxo-1,6-thiomorpholin-4-yl)-4-(2-methyl)isobutyramide”

(Co7D 285/02)

139397

The invention relates to the compound
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1,6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1,6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,

Which may be used for the treatment of migraine, rheumatoid arthritis, asthma, bronchial hyperreactivity, inflammatory bowel disease or for the treatment of disorders including Parkinson's disease, anxiety, depression, pain, headache, Alzheimer's disease, multiple sclerosis, oedema, allergic rhinitis, crohn's disease, ocular injury, ocular inflammatory diseases, psychosis, motion sickness, induced vomiting, emesis, urinary incontinence, psychoimmunologic or psychosomatic disorders, cancer, withdrawal symptoms of addictive drugs from opiates or nicotine, traumatic brain injury or benign prostatic hyperplasia.

700/2002 Recordati Ireland
Limited.
Ireland.

“Novel crude and crystalline form of lercanidipine hydrochloride.”

(Co7D 21/90)

139398

The invention describes novel lercanidipine crude Forms (A) and (B), novel lercanidipine hydrochloride crystalline Forms (I) and (II) obtained from said crude Forms, pharmaceutical, antihypertensive compositions containing as active agent at least one of the lercanidipine hydrochloride crystalline Forms (I) and (II) and methods of use thereof.

835/2002 Syngenta Participations
AG.
Switzerland.


“Herbicidal composition containing a tetrahydropyrazolodione herbicide and mesosulfuron or flufenacet as co-herbicide”

(A01N 35/10)

139399

Herbicidal composition comprising

a) a herbicidally effective amount of a compound of formula I.



Wherein the substituents and

b) an amount, effective for herbicide synergy, of mesosulfuron, mesotrione or flufenacet.

894/2002 Bayer CropScience S.A.
France.

“Synergistic fungicidal composition comprising a pyridylmethylbenzamide compound and a dithiocarbamate compound”

(A01N 37/18, A01N 37/26)

139400

1) Fungicidal compositions comprising:

a) at least one pyridylmethylbenzamide derivative of formula (I), in which the various radicals are as defined in the description, and

b) at least one compound (II) chosen from dithiocarbamates, preferably fungicidal dithiocarbamates, and, still more preferably from the following active agents: ferbam, mancozeb, maneb, metiram, nabam, nickel bis (dimethyldithio-carbamate), propineb, zineb and mixtures thereof;

and their agriculturally acceptable isomers and addition salts with an acid. 2) Method for the curative or preventive control of phytopathogenic fungi of crops using an effective and non-phytotoxic quantity of one of these fungicidal compositions.

1031/2002 Merck & Co., Inc.
USA

“A nanoparticulate composition comprising the compound 2-(1-(1-(R)-3, 5-bis(trifluoromethyl) phenyl) ethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-(5-oxo-1H, 4H-1, 2, 4-triazolo) methylmorpholine)”

(A61K 31/4196)

139401

The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical composition of this invention useful in the treatment or prevention of disorders such as psychiatric disorders including depression and anxiety, inflammatory diseases and emesis.


1132/2002 Bristol-Myers Squibb
Company
USA

“A tricyclic 2-pyrimidone compound”

(CO7D 471/04)

139402

The present invention relates to tricyclic 2-pyrimidone compounds of formula (I):



Or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.


1095/2003 Pfizer Products Inc.,
USA

“Pyrimidine compound”

(CO7D 401/14)

139403

The present invention relates to a compound of the formula 1



Wherein R¹-R⁴ are as defined herein. Such novel pyrimidine are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The invention also relates to a method of using such compound in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical composition containing such compound.

PROCEEDING UNDER SECTION 45 OF THE ORDINANCE 2000.

Notice is hereby given that an application under section 45 of the Patent Ordinance, 2000 for restoration of a lapsed Patent No.135699 dated:-26.2.97 Priority date 26.2.96 (India) for the invention entitled, “A Synergistic Jute and/or Allied Fibre Lubricating Composition for Improvement in Productivity in Jute Industry”.

Which ceased on 26.2.2006 has been left at the Patent Office 25.8.2007 Indian Jute Industries Research Association, 17, Taratola Road, Calcutta -700-088, India.

Any person may give notice of opposition to the restoration by lodging form P-7 of the Patent rules 2003 ,accompanied by the prescribed fee of Rs.750/- of the Patent Office, 2nd Floor Kandawala Building M.A. Jinnah Road, Karachi within two months from the date of advertisement in the Gazette.

Will appear in the Gazette_____2008.

N O T I F I C A T I O N

PROCEEDING UNDER SECTION 42 OF THE PATENT ORDINANCE

2000.

Any person may give notice of opposition to the amendment proposed in the under mentioned patent No.138140 dated 15.3.2002 (Priority date 7.2.2002) Singapore. Lodging form 6 of the patent Rules 2003 together with the prescribed fee of Rs.750/- at any time within Two months from the date of advertisement in the Gazette, at the patent office, 2nd Floor Kandawala Building M.A. Jinnah Road, Karachi.

Trek 2000 International Ltd, (a company organized and existing under the laws of Singapore), of 30 Loyang Way # 07-13/14/15, Loyang Industrial Estate, SINGAPORE 508769.

SEEK TO AMEND THE Specification/Claims above for invention entitled ,”A PROTABLE DATA STORAGE AND IMAGE RECORDING DEVICE CAPABLE OF DIRECT CONNECTION TO A COMPUTER USB PORT”.

The proposed amendment is desired by way of correction.

The proposed amendment may be inspected in the patent office.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 52(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 136378 of 5-5-98, Granted to:- Elcor Corporation, a corporation of Delaware, United States of America, located at Wellington Centre, Suite 1000 14643 Dallas Parkway Dallas, Texas 75240, U.S.A., and later on Merged to ELKCORP, a corporation of Delaware of Wellington Centre, Suite 1000, 14643 Dallas Parkway Dallas, Texas 75240-8871, United States of America.

The following entry has been made in the Register of Patents:-

Orloff Engineers Ltd, a Texas Corporation with an address at 415 W. Wall, Suite 2000, Midland, Texas 79701-4438, as proprietor by virtue of Deed of Assignment dated 31st May 2005, made between, ELKCORP, as Assignor of the one part and, Orloff Engineers Ltd as Assignee of the other parts.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 (1) AND RULE 37(a) OF THE
PATENTS ORDINANCE 2000**

In the matter of Patent No. 133958 of 12-10-93 (Priority date 28-9-93 Canada) granted to:- Fording Coal Limited (a Canadian Company) # 200, 205 – 9th Avenue S.E., Calgary, Alberta, Canada T2G OR4.

In Pursuance of an application received on 15-8-2007.

The following entry has been made in the Register of Patents:-

Elk Valley Coal Partnership (a partnership governed by the laws of the province of Alberta, Canada) of Suit 1000, 205 Ninth Avenue Se Alberta, Canada T2G OR3 as proprietor by virtue of Deed of Assignment dated 28th February, 2003, made between, Fording Coal Limited, as Assignor of the one part and, Elk Valley Coal Partnership as Assignee of the other parts.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 139102 of 21-9-2004 Priority date 23-9-2003 (Europe) Granted to:-
Clariant International Ltd, of Rothausstrasse 61, CH-4132 Muttenz, Switzerland.

In pursuance of an application received on 15-11-2007.

The following entry has been made in the Register of Patents:-

Clariant Finance (BVI) Limited, of Citco Building, Wickhams, Cay, P.O. Box 662, Road
Town, Tortola, British Virgin Island, as Proprietor by virtue of deed of Assignment dated 24th November,
2006 made between Clariant International Ltd, as Assignor of One Part and **Clariant Finance (BVI)
Limited** as Assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 139093 of 8-12-2004 Priority date 10-12-2003 (Europe).
Granted to: - **Clariant International Ltd.**, of Rothausstrasse 61, CH-4132 Muttenz,
Switzerland.

In pursuance of an application received on 15-11-2007.

The following entry has been made in the Register of Patents:-

Clariant Finance (BVI) Limited, of Citco Building, Wickhams, Cay, P.O. Box 662,
Road Town, Tortola, British Virgin Island. as proprietor by virtue of deed of
Assignment dated 24th November, 2006 made between **Clariant International Ltd.**,
as Assignor of the One Part and **Clariant Finance (BVI) Limited** as assignee of the
Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 139048 of 18-8-2004 Priority date 21-8-2003 (Switzerland). Granted to: - **Clariant International Ltd.**, of Rothausstrasse 61, CH-4132 Muttenz, Switzerland.

In pursuance of an application received on 15-11-2007.

The following entry has been made in the Register of Patents:-

Clariant Finance (BVI) Limited, of Citco Building, Wickhams, Cay, P.O. Box 662, Road Town, Tortola, British Virgin Island, as proprietor by virtue of deed of Assignment dated 24-11-2006 made between **Clariant International Ltd**, as Assignor of the One Part and **Clariant Finance (BVI) Limited** as assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000.**

In the matter of Patent No. 137266 of 29-3-2000 Priority date 30-3-99 (UK). Granted to: - **CONCENTRIC PUMPS LIMITED**, a British Company of Unit 10 Gravelly Industrial Park, Erdington, Birmingham, B24 8HW, United Kingdom.

In pursuance of an application received on 31-01-2007.

The following entry has been made in the Register of Patents:-

Concentric plc, a British Company of 3 The Arehway, Radford Road, Alvechurch B48 7LD, United Kingdom., as proprietor by virtue of deed of assignment dated 05-10-2006 made between **CONCENTRIC PUMPS LIMITED** as assignor of the ONE PART and **Concentric plc** as assignee of the OTHER PART.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 138646 of 23-8-2003 Priority Date 24-8-2002 (Germany). Granted to:- **Schott Glas**, a German Company of HattenbergstraBe 10 D-55122 Mainz, Germany.

In pursuance of an application received on 10-10-2006

The following entry has been made in the Register of Patents:-

SCHOTT AG, a German company, having its office at hattenbergstraBe 10, D-55122 Mainz, Germany as proprietor by virtue of Deed of Assignment dated 12th September, 2006 made between Schott Glas, as Assignor of the ONE PART and SCHOTT AG as Assignee of the OTHER PARTS.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 134195 of 25-7-1994, Granted to:- **BASF AKTIENGESELLSCHAFT** (a German Joint Stock Company Organized and existing under the laws of the Federal Republic of Germany), of 67056 Ludwigshafen, Germany.

In pursuance of an application received on 13-6-2006.

The following entry has been made in the Register of Patents:-

Dystar Textilfarben GmbH & Co. Deutschland KG (a German Company), of **D-65926 Frankfurt am Main, Germany**, as proprietor by virtue of Deed of Assignment dated 13th April, 2006 made between **BASF AKTIENGESELLSCHAFT**, as Assignor of the **ONE PART** and **Dystar Textilfarben GmbH & Co. Deutschland KG**, the Assignee of the **OTHER PART**.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 137001 of 13-7-1999 Priority Date 13-7-1998 (Germany) Granted to:-
BASF AKTIENGESELLSCHAFT (a German Joint Stock Company Organized and existing under the laws of the Federal Republic of Germany), of 67056 Ludwigshafen, Germany.

In pursuance of an application received on 13-6-2006.

The following entry has been made in the Register of Patents:-

Dystar Textilfarben GmbH & Co. Deutschland KG (a German Company), of **D-65926 Frankfurt am Main, Germany**, as proprietor by virtue of Deed of Assignment dated 13th April, 2006 made between **BASF AKTIENGESELLSCHAFT**, as Assignor of the **ONE PART** and **Dystar Textilfarben GmbH & Co. Deutschland KG**, the Assignee of the **OTHER PART**.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 135797 of 07-6-1997, Granted to:- **BASF AKTIENGESELLSCHAFT** (a German Joint Stock Company Organized and existing under the laws of the Federal Republic of Germany), of 67056 Ludwigshafen, Germany.

In pursuance of an application received on 13-6-2006.

The following entry has been made in the Register of Patents:-

Dystar Textilfarben GmbH & Co. Deutschland KG (a German Company), of D-65926 Frankfurt am Main, Germany, as proprietor by virtue of Deed of Assignment dated 13th April, 2006 made between **BASF AKTIENGESELLSCHAFT**, as Assignor of the **ONE PART** and **Dystar Textilfarben GmbH & Co. Deutschland KG**, the Assignee of the **OTHER PART**.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 135103 of 28-1-96, Granted to:- **BASF AKTIENGESELLSCHAFT** (a German Joint Stock Company Organized and existing under the laws of the Federal Republic of Germany), of 67056 Ludwigshafen, Germany.

In pursuance of an application received on 13-6-2006.

The following entry has been made in the Register of Patents:-

Dystar Textilfarben GmbH & Co. Deutschland KG (a German Company), of D-65926 Frankfurt am Main, Germany, as proprietor by virtue of Deed of Assignment dated 13th April, 2006 made between BASF AKTIENGESELLSCHAFT, as Assignor of the ONE PART and Dystar Textilfarben GmbH & Co. Deutschland KG, the Assignee of the OTHER PART.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 134148 of 7-3-1994, Granted to:- **BASF AKTIENGESELLSCHAFT** (a German Joint Stock Company Organized and existing under the laws of the Federal Republic of Germany), of 67056 Ludwigshafen, Germany.

In pursuance of an application received on 13-6-2006.

The following entry has been made in the Register of Patents:-

Dystar Textilfarben GmbH & Co. Deutschland KG (a German Company), of D-65926 Frankfurt am Main, Germany, as proprietor by virtue of Deed of Assignment dated 13th April, 2006 made between **BASF AKTIENGESELLSCHAFT**, as Assignor of the **ONE PART** and **Dystar Textilfarben GmbH & Co. Deutschland KG**, the Assignee of the **OTHER PART**.

NOTIFICATION

PROCEEDING UNDER SECTION 42 OF PATENT ORDINANCE, 2000

Any person may give notice of opposition to the amendment proposed in the under mentioned patent No. 138132 dated 15-3-2002. Priority date 12-3-2002 Singapore. lodging Form 7 of the Patent Rules, 2003 together with the prescribed fee of Rs. 750/- at any time within two months from the date of advertisement in the Gazette, at the Patent Office, 2nd Floor Kandawala Building, M.A. Jinnah Road, Karachi.

Trek 2000 International Ltd, (a company organized and existing under the laws of Singapore) 30
Loyang Way # 07 -13/14/15, Loyang Industrial Estate, Singapore 508769.

SEEK TO AMEND THE Specification, Claims as above for invention entitled “System and apparatus for accessing and transporting electronic communication using a portable storage device”.

The proposed amendment is desired by way of correction.

The proposed amendment may be inspected in the Patent Office.

**REGISTRATION OF ASSIGNMETN UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 136735 of 24-3-1999 Granted to:- UCB, S.A. Alle De la Recherche, 60, B-1070 BRUXELLES (Belgium). (a Belgian company).

In pursuance of an application received on 19-7-2006.

The following entry has been made in the Register of Patents:-

NEOGEN CORPORATION (a Michigan corporation), of 620 Leshar Place, Lansing, Michigan 48912, U.S.A. as Proprietor by virtue of deed of Assignment dated 12th April, 2006 made between UCB S.A, as Assignor of One Part and Neogen Corporation as Assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 136500 of 2-10-1998 Granted to:- UCB Bioproducts, S.A, of Allee de la recherche 60, B-1080 Bruxelles, Belgium, (a Belgian Company) whose name was changed to UCB S.A.

In pursuance of an application received on 19-7-2006.

The following entry has been made in the Register of Patents:-

NEOGEN CORPORATION (a Michigan corporation), of 620 Leshar Place, Lansing, Michigan 48912, U.S.A. as Proprietor by virtue of deed of Assignment dated 12th April, 2006 made between UCB S.A, as Assignor of One Part and Neogen Corporation as Assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 138446 of 15-2-2003 Priority date 22-2-2002 (UK) Granted to:- **BP Chemicals Limited** (a British company) of Britannic House, 1 Finsbury Circus London, EC2M 7BA, United Kingdom.

In pursuance of an application received on 16-9-2006.

The following entry has been made in the Register of Patents:-

INEOS EUROPE LIMITED, (a British company), of Compass Point, 79-87 Kingston Road, Staines, middlesex, TW18 1DT, United Kingdom, as Proprietor by virtue of deed of Assignment dated for the year 2006 made between **BP Chemicals Limited**, as Assignor of One Part and **INEOS EUROPE LIMITED** as Assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 138397 of 04-2-2003 Priority date 09-2-2002 (GB) Granted to:- **BP Chemicals Limited** (a British company) of Britannic House, 1 Finsbury Circus London, EC2M 7BA, United Kingdom.

In pursuance of an application received on 16-9-2006.

The following entry has been made in the Register of Patents:-

INEOS EUROPE LIMITED, (a British company), of Compass Point, 79-87 Kingston Road, Staines, middlesex, TW18 1DT, United Kingdom, as Proprietor by virtue of deed of Assignment dated for the year 2006 made between **BP Chemicals Limited**, as Assignor of One Part and **INEOS EUROPE LIMITED** as Assignee of the Other Part.

*PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE
OF NAME IN THE REGISTER OF PATENTS.*

In the matter of Patent No. 134415 dated 14-9-1994 Priority date, Granted to:- **Glaxo Inc**, Five Moore Drive Research Triangle Park, north Carolina 27709, United States of America,

In pursuance of an application received on 25-8-2007.

The following entry has been made in the Register of Patents:-

The name of the patentee has been changed to: **Glaxo Wellcome Inc**,

**REGISTRATION OF MERGER UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 134415 of 14-9-1994 Granted to:- **Glaxo Inc**, Five Moore Drive Research Triangle Park, north Carolina 27709, United States of America, and later on whose name was changed to Glaxo Wellcome Inc.

In pursuance of an application received on 25-8-2007.

The following entry has been made in the Register of Patents:-

SmithKline Beecham Corporation (a corporation organized under the laws of the Commonwealth of Pennsylvania, one of the United States of America), of One Franklin Plaza, Philadelphia, pennsylvania 19103, United States of America. as proprietor by virtue of merger between **Glaxo Wellcome Inc**, the terminating entity (or merged entity) into SmithKline Beecham Corporation as the surviving entity as per merger certificate dated 24th April, 2007.

**REGISTRATION OF ASIGNMENT UNDER SECTION 55(1) RULE 37(a) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 134436 of 19-10-1994 Priority date 22-10-1993 (UK) Granted to:-
SOCIETE CIVILE DES BREVETS HENRI VIDAL. A French company of 36, avenue Raymond
Poincare 75116 Paris, France.

In pursuance of an application received on 13-12-2007.

The following entry has been made in the Register of Patents:-

TERRE ARMEE INTERNATIONALE S.A.S., a French company of 1 bis rue due Petit Clamart,
Velizy, Villacoublay, 78140, France, a Proprietor by virtue of transfer of right by Dissolution / Winding-
Up without liquidation of the Societe Civile Des Brevets Henri Vidal into TERRE ARMEE
INTERNATIONALE S.A.S. dated 10-2-2005.

**REGISTRATION OF ASIGNMENT UNDER SECTION 55(1) RULE 37(a) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 135780 of 10-4-1997 Granted to:- **SOCIETE CIVILE DES BREVETS HENRI VIDAL**. A French company of 36, avenue Raymond Poincare 75116 Paris, France.

In pursuance of an application received on 13-12-2007.

The following entry has been made in the Register of Patents:-

TERRE ARMEE INTERNATIONALE S.A.S., a French company of 1 bis rue due Petit Clamart, Velizy, Villacoublay, 78140, France, a Proprietor by virtue of transfer of right by Dissolution / Winding-Up without liquidation of the Societe Civile Des Brevets Henri Vidal into TERRE ARMEE INTERNATIONALE S.A.S. dated 10-2-2005.

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 134541 dated 13.12.1994 granted to ASTA MEDICA AKTIENGESELLSCHAFT,(a German Company), of an der pikardie 10,D-01277 Dresden Germany and later on Assigned to ZENTARIS A.G.,(a German Company)
Of WeismullerstraBe 45, 60314 Frankfurt/ Main, Germany.

In presence of an application received on 27.11.2007.the following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "ZENTARIS GMBH.

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 133771 dated 21.6.1993 granted to ASTA MEDICA AKTIENGESELLSCHAFT,(a German Company), of an der pikardie 10,D-01277 Dresden Germany .and later on Assigned to ZENTARIS A.G., (a German Company) of WeismullerstraBe 45, 60314 Frankfurt/ Main, Germany.

In presence of an application received on 27.11.2007.the following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "ZENTARIS GMBH.

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 138379 dated 21.6.1993 granted to DAHCHI SUNTORY PHARMA CO.,LTD (a Japanese company), of 5-7-2,Kojimachi, Chiyoda-ku, Tokyo 102-8530, JAPAN. Whose name was changed to DAHCHI ASUBIO PHARMA CO., LTD, (a Japanese company), of 9-11, Akasaka 2-chome, Minato-ku, Tokyo 107-8541, Japan.

In presence of an application received on 15.12.2007.the following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "ASUBIO PHARMA CO., LTD.

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 137882 dated 29.6.2001 priority date 30.6.2000 (Japan) granted to DAHCHI SUNTORY PHARMA CO.,LTD (a Japanese company), of 5-7-2,Kojimachi, Chiyoda-ku, Tokyo 102-8530, JAPAN. Whose name was changed to DAHCHI ASUBIO PHARMA CO., LTD, (a Japanese company), of 9-11, Akasaka 2-cho me, Minato-ku, Tokyo 107-8541, Japan.

In presence of an application received on 15.12.2007.the following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "ASUBIO PHARMA CO., LTD.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 138319 of 28-9-2002, Granted to:- **ERASMUS UNIVERSITEIT ROTTERDAM** (A Dutch Nationality), of Dr. Molewaterplein 50 3015 GE Rotterdam The Netherlands.

In pursuance of an application received on 18-5-2007.

The following entry has been made in the Register of Patents:-

BIOTEMPT B.V. (a Dutch company), of Hoge Linthorst 1, 7958 NZ Koekange, The Netherlands. as proprietor by virtue of Deed of Assignment dated 26th July, 2005 made between **ERASMUS UNIVERSITEIT ROTTERDAM**, as Assignor of the **ONE PART** and **BIOTEMPT B.V.**, the Assignee of the **OTHER PART**.

**REGISTRATION OF ASIGNMNT UNDER SECTION 52(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 138321 of 4-10-2002 Priority Date 4-10-2001 (Europe) Granted to:-
ERASMUS UNIVERSITEIT ROTTERDAM (A Dutch Nationality), of Dr. Molewaterplein 50 3015
GE Rotterdam The Netherlands.

In pursuance of an application received on 18-5-2007.

The following entry has been made in the Register of Patents:-

BIOTEMPT B.V. (a Dutch company), of Hoge Linthorst 1, 7958 NZ Koekange, The Netherlands. as
proprietor by virtue of Deed of Assignment dated 26th July, 2005 made between **ERASMUS**
UNIVERSITEIT ROTTERDAM, as Assignor of the **ONE PART** and **BIOTEMPT B.V.**, the Assignee
of the **OTHER PART**.

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 135744 dated 20.6.97 the Standard Oil Company, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601, USA and later on Assigned to O & D USA LLC (a limited liability company organized under the law of the state of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601 and again whose name was changed to INNOVENE USA LLC.

In presence of an application received on 20.11.2006.

The following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "INEOS USA LLC".

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 137855 of (Anti date: 23-5-2001) Priority Date 25-5-2000 (USA) Granted to:- **1. SMITHKLINE BEECHAM CORPORATION** (a corporation organized under the laws of the Commonwealth of Pennsylvania, one of the United States of America of One Frankline Plaza, Philadelphia, Pennsylvania 19103, United States of America. **2. Glaxo Group Limited**, (a British company), of Glaxo Wellcome House, Berkley Avenue Greenford, Middlesex, UB6 ONN, United Kingdom.

In pursuance of an application received on 24-10-2007.

The following entry has been made in the Register of Patents:-

SmithKline Beecham Corporation (a corporation organized and existing under the laws of the Commonwealth of Pennsylvania, USA) of One Franklin Plaza, Philadelphia, Pennsylvania 19103, USA. as proprietor by virtue of Deed of Assignment dated 9th July, 2007 made between **Glaxo Group Limited**, as Assignor of the **ONE PART** and **SmithKline Beecham Corporation**, the Assignee of the **OTHER PART**.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 137844 of 23-5-2001 Priority Date 25-5-2000 (USA) Granted to:- **1. SMITHKLINE BEECHAM CORPORATION** (a corporation organized under the laws of the Commonwealth of Pennsylvania, one of the United States of America of One Frankline Plaza, Philadelphia, Pennsylvania 19103, United States of America. **2. Glaxo Group Limited**, (a British company), of Glaxo Wellcome House, Berkley Avenue Greenford, Middlesex, UB6 ONN, United Kingdom.

In pursuance of an application received on 24-10-2007.

The following entry has been made in the Register of Patents:-

SmithKline Beecham Corporation (a corporation organized and existing under the laws of the Commonwealth of Pennsylvania, USA) of One Franklin Plaza, Philadelphia, Pennsylvania 19103, USA. as proprietor by virtue of Deed of Assignment dated 9th July, 2007 made between **Glaxo Group Limited**, as Assignor of the **ONE PART** and **SmithKline Beecham Corporation**, the Assignee of the **OTHER PART**.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 138766 of 29-1-2004 Priority date 31-1-2003 (Europe).
Granted to: - **Clariant International Ltd.**, of Rothausstrasse 61, CH-4132 Muttenz,
Switzerland.

In pursuance of an application received on 26-3-2007.

The following entry has been made in the Register of Patents:-

Clariant Finance (BVI) Limited, of Citco Building, Wickhams, Cay, P.O. Box 662,
Road Town, Tortola, British Virgin Island, as proprietor by virtue of deed of
Assignment dated 24-11-2006 made between **Clariant International Ltd**, as
Assignor of the One Part and **Clariant Finance (BVI) Limited** as assignee of the
Other Part.

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 136580 dated 7.9.1998 the Standard Oil Company, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601,USA and later on Assigned to O & D USA LLC (a limited liability company organized under the law of the state of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601.

In presence of an application received on 20.11.2006.

The following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "INNOVENE USA LLC.

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 136580 dated 7.9.98 the Standard Oil Company, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601,USA and later on Assigned to O & D USA LLC (a limited liability company organized under the law of the state of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601 and again whose name was changed to INNOVENE USA LLC.

In presence of an application received on 20.11.2006.

The following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "INEOS USA LLC".

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 135744 dated 20.6.97 the Standard Oil Company, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601,USA and later on Assigned to O & D USA LLC (a limited liability company organized under the law of the state of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601.

In presence of an application received on 20.11.2006.

The following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "INNOVENE USA LLC.

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 136270 dated 21.2.98 the Standard Oil Company, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601,USA and later on Assigned to O & D USA LLC (a limited liability company organized under the law of the state of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601.

In presence of an application received on 20.11.2006.

The following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "INNOVENE USA LLC.

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 136270 dated 21.2.98 the Standard Oil Company, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601, USA and later on Assigned to O & D USA LLC (a limited liability company organized under the law of the state of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601 and again whose name was changed to INNOVENE USA LLC.

In presence of an application received on 20.11.2006.

The following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "INEOS USA LLC".

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 135496 dated 6.1.97 the Standard Oil Company, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601,USA and later on Assigned to O & D USA LLC (a limited liability company organized under the law of the state of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601 and again whose name was changed to INNOVENE USA LLC.

In presence of an application received on 20.11.2006.

The following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "INEOS USA LLC".

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 135496 dated 6.1.97 the Standard Oil Company, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601,USA and later on Assigned to O & D USA LLC (a limited liability company organized under the law of the state of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601.

In presence of an application received on 20.11.2006.

The following entry has been made in the Register of Patents

The Name of the patentee has been changed to: "INNOVENE USA LLC.

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 137128 dated 23.10.1999 granted to Road building International (Barbados)Limited, (a company organized with limited liability in accordance with the laws of Barbados and of Financial Services Centre, P O Box, 111,Bishepecourt Hill, St Michael, Barbados, West Indies.

In presence of an application received on 25.2.2008.the following entry has been made in the Register of Patents

The Name of the patentee has been changed to: Any Way Solid Environmental Solutions (Barbados) Limited.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 137128 of 23-10-1999 Granted to:- **Road building International (Barbados) Limited**, (a company organized with limited liability in accordance with the laws of Barbados), of PO Box 111, bishops court Hill, St. Michael, barbados, West Indies, and later on whose name was changed to **Any Way Solid Environmental Solutions (Barbados) Limited**.

In pursuance of an application received on 25-2-2008.

The following entry has been made in the Register of Patents:-

Fowlds Limited, C/O Equity Trust (Guemsey) Limited PO Box 124, Mignot Plateau, St Peter Port, Guemsey GY1 4EG, as proprietor by virtue of Deed of Assignment dated 15th January, 2008 made between **Any Way Solid Environmental Solutions (Barbados) Limited**, as Assignor of the **ONE PART** and **Fowlds Limited**, the Assignee of the **OTHER PART**.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 137384 of 3-6-2000 Priority Date 4-6-1999 (USA & EPA) Granted to:- **Western Seed Espana** (a Spanish company), of Bajada de Vargas S/N Playa de Vargas Ingenio Las Palmas De Gran Canaria Spain.

In pursuance of an application received on 30-4-2007.

The following entry has been made in the Register of Patents:-

Western Seed International B.V. (a Spanish company), of Bajada de Vargas S/N Playa de Vargas Ingenio Las Palmas De Gran Canaria Spain, as proprietor by virtue of Deed of Assignment dated 28th February, 2007 made between **Western Seed Espana** as Assignor of the **ONE PART** and **Western Seed International B.V.** the Assignee of the **OTHER PART**.

*PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE
OF ADDRESS IN THE REGISTER OF PATENTS.*

In the matter of Patent No. 133730 dated 30-5-93 Granted to: - Rhone-Poulenc Agrochimie, a French body corporate of 14-20 Rue Pierre Baizet, 69009 Lyon, France, In pursuance of an application received on 25-10-2007

The following entry has been made in the Register of Patents:-

The Name/Address of the patentee has been changed to: Bayer CropScience S.A. of 16 rue J.M. Leclair, F-69009 Lyon.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(1) RULE 36(1) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 133730 of 30-5-1993 granted to:- Rhone-Poulenc Agrochimie, a French body corporate of 14-20 Rue Pierre Baizet, 69009 Lyon, France, whose name was changed to Bayer CropScience S.A. of 16 rue J.M. Leclair, F-69009 Lyon.

In pursuance of an application received on 25-7-2007

The following entry has been made in the Register of Patents:-

Nippon Soda, a Japanese company, with an office at 2-1, 2-chome Otemachi, Chiyoda-ku Tokyo 100-8165 Japan as proprietor by virtue of Deed of Assignment dated 24th August, 2005 made between, Bayer CropScience S.A, as Assignor of the one part and, Nippon Soda, as Assignee of the other parts.

PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN THE REGISTER OF PATENT.

In the matter of Patent No. 138582 dated 22-9-2003 priority date 23-9-2002 (GB) granted to “Baby Innovations & Marketing Servicios Internacionales SA’ .of 3rd Floor, 38 Esplanade, St. Helier, Jersey United Kingdom JE4 8QL.

In presence of an application received on 05-10-2005.the following entry has been made in the Register of Patents

The Name of the patentee has been changed to ”Baby Innovations-Marketing E Servicios Internacionais S.A”.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 135361 of 26-6-1996 granted to:- **Merck Patent Gesellschaft mit Beschränkter Haftung Darmstadt**, A German Body Corporate, of 64271 Darmstadt, Frankfurter Strasse 250, Germany.

In pursuance of an application received on 18-5-2007.

The following entry has been made in the Register of Patents:-

Tioga Pharmaceuticals, Inc, a corporation organized under the laws of Delaware, and having its principal place of business at c/o Forward Ventures, 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, USA as proprietor by virtue of Deed of Assignment dated 15th August 2006 made between, **Merck Patent Gesellschaft mit Beschränkter Haftung Darmstadt**, as Assignor of the one part and, **Tioga Pharmaceuticals, Inc** as Assignee of the other parts.

**REGISTRATION OF ASSIGNMETN UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 133603 of 1-03-1993 granted to:- SCHERING AKTIENGESELLSCHAFT, a company organized and existing under the lsws of West Germany, Manufacturers, of 170-172 Muellerstrasse D-1 Berlin 65, Germany (West), and Waldstrasse 14, D 5619 Bergkamen Germany (West).

In Pursuance of an application received on 22-07-2007

The following entry has been made in the Register of Patents:-

EVMS (Eastern Virginia Medical School), 721 Fairfax Ave., Norfolk, VA 23507, USA, as proprietor by virtue of Deed of Assignment dated 6th December, 2006 made between, SCHERING AKTIENGESELLSCHAFT, as Assignor of the one part and, EVMS (Eastern Virginia Medical School), as Assignee of the other parts.

**REGISTRATION OF ASIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 135990 of 25-10-97 granted to:- Elcor Corporation., a corporation of Delaware of Wellington Centre, Suite 1000 14643 Dallas Parkway Dallas, Texas 75240, USA and later on merged into Elcorp, a corporation of Delaware of Wellington Centre, Suite 1000, 14643 Dallas Parkway Dallas Texas 75240 – 8871 United States of America.

In Pursuance of an application received on 01-03-2007.

The following entry has been made in the Register of Patents:-

Ortloff Engineers, Ltd, a Texas Corporation with an address at 415 W. Wall, Suite 2000, Midland, Texas 79701-4438, as proprietor by virtue of Deed of Assignment dated 31st May, 2005 made between, Elcor Corporation, as Assignor of the one part and, Ortloff Engineers, Ltd as Assignee of the other parts.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000.**

In the matter of Patent No. 135496 of 6-1-97, Granted to:- **The Standard Oil Company**, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601, United States of America.

In pursuance of an application received on 20-11-2006.

The following entry has been made in the Register of Patents:-

O & D USA LLC. (a limited liability company organized under the laws of the State of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601, as Proprietor by virtue of deed of Assignment dated 1st April, 2005 made between **The Standard Oil Company**, as Assignor of One Part and **O & D USA LLC** as Assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000.**

In the matter of Patent No. 136270 of 21-2-1998, Granted to:- **The Standard Oil Company**, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601, United States of America.

In pursuance of an application received on 20-11-2006.

The following entry has been made in the Register of Patents:-

O & D USA LLC. (a limited liability company organized under the laws of the State of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601, as Proprietor by virtue of deed of Assignment dated 1st April, 2005 made between **The Standard Oil Company**, as Assignor of One Part and **O & D USA LLC** as Assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000.**

In the matter of Patent No. 135744 of 20-6-97, Granted to:- **The Standard Oil Company**, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601, United States of America.

In pursuance of an application received on 20-11-2006.

The following entry has been made in the Register of Patents:-

O & D USA LLC. (a limited liability company organized under the laws of the State of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601, as Proprietor by virtue of deed of Assignment dated 1st April, 2005 made between **The Standard Oil Company**, as Assignor of One Part and **O & D USA LLC** as Assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000.**

In the matter of Patent No. 136580 of 7-9-7998, Granted to:- **The Standard Oil Company**, an Ohio Corporation, 200 East Randolph Drive, Chicago, Illinois, 60601, United States of America.

In pursuance of an application received on 20-11-2006.

The following entry has been made in the Register of Patents:-

O & D USA LLC. (a limited liability company organized under the laws of the State of Delaware, USA whose principal office is at 200E Randolph Drive, Chicago, Illinois USA 60601, as Proprietor by virtue of deed of Assignment dated 1st April, 2005 made between **The Standard Oil Company**, as Assignor of One Part and **O & D USA LLC** as Assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 137641 of 31-3-2001 Priority Date 5-4-2000 (Japan) Granted to:- **1. Honda Giken Kogyo Kabushiki Kaisha**, (a corporation of Japan), having a place of business at 1-1, Minami-Aoyama 2-chome, Minato-ku, Tokyo, Japan. **2. Nippon Leakless Kogyo Kabushiki Kaisha** (a corporation of Japan), of 2-33-8, Nishi-shinbashi, Minato-ku, Tokyo, Japan.

In pursuance of an application received on 23-7-2007.

The following entry has been made in the Register of Patents:-

Honda Giken Kogyo Kabushiki Kaisha, (a corporation of Japan), having a place of business at 1-1, Minami-Aoyama 2-chome, Minato-ku, Japan, as proprietor No. 2 by virtue of Deed of Assignment for the year 2007 made between **Nippon Leakless Kogyo Kabushiki Kaisha**, as Assignor of the **ONE PART** and **Honda Giken Kogyo Kabushiki Kaisha**, the Assignee of the **OTHER PART**.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55 OF THE PATENTS ORDINANCE
2000**

In the matter of Patent No. 133508 of 07-03-1993 Granted to:- **1.** Vita-Invest, S.A., of C. FontSanta, 12-14 08970 Sant Joan Despi, (Barcelona) Spain **2.** QUIMICA SINTETICA, S.A. OF C. Dulcinea, s/n 28805 Alcala de Henares (Medrid, Spain) both are Spanish companies, later on by virtue of Deed of assignment Quimica sintetica, S.A assigned this Patent to VITA- INVEST. S.A. and VITA-INVEST. S.A. assigned to Laboratorios Vita, S.A., domiciled at Av., De Barcelona, 69, 08970 Sant Joan Despi, Barcelona, Spain. And again assigned to Vita Cientifica, a Spanish company of Avenida Barcelona 69, 08970- Sant Joan Despi, Spain.

In pursuance of an application received on 10-12-2007.

The following entry has been made in the Register of Patents:-

Inke, S.A, a Spanish company of Pol. Ind. Can Pelegri, C.Argent, 1, 08755 Castellabisbal (Barcelona), Spain, as proprietor by virtue of Deed of Assignment dated 31st October, 2007 made between **Vita Cientifica, S.L**; as Assignor of the one part and **Inke, S.A** as Assignee of the other parts.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 134567 of 24-1-1995, Granted to: - **Plurichemie Anstalt.**,
a Corporate body of Liechtenstein, of P.O.Box 34722, Vaduz, Liechtenstein.

In pursuance of an application received on 28-8-2007.

The following entry has been made in the Register of Patents:-

Hovione Inter Limited of Bahnhofstrasse 21, CH-6000 Lucerne 7, Switzerland. as
proprietor by virtue of deed of Assignment dated 1st August. 2007 made between
Plurichemie Anstalt, as Assignor of the One Part and **Hovione Inter Limited** as
assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 135712 of 10-3-1997, Granted to: - **QLT PHOTOTHERAPEUTICS, INC**, a Canadian Corporation of 520 West 6th Avenue, Vancouver, British Columbia, Canada V5Z 4H5, Canada whose name was changed to **QLT Inc**.

In pursuance of an application received on 14-4-2005.

The following entry has been made in the Register of Patents:-

Novartis AG, of Lichstrasse, 35, CH-4056 Basel, Switzerland, as proprietor by virtue of deed of Assignment dated 01-01-2005 made between **QLT INC**, as Assignor of the One Part and **Novartis AG**, as assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 136341 of 3-4-1998, Granted to: - **Plurichemie Anstalt.**, a Liechtenstein Corporation of FL-9490, Vaduz, Liechtenstein.

In pursuance of an application received on 28-8-2007.

The following entry has been made in the Register of Patents:-

Hovione Inter Limited, of Bahnhofstrasse 21, CH-6000 Lucerne 7, Switzerland, as proprietor by virtue of deed of Assignment dated 1st August, 2007 made between **Plurichemie Anstalt**, as Assignor of the One Part and **Hovione Inter Limited** as assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 138982 of 24-6-2004 Priority date 26-6-2003 (USA).
Granted to: - **Pepharms R & D Limited**, HK Private Limited Company, of Unit 2106,
21st Floor, Island Place Tower, 510 King's Road, North Point, Hong Kong.

In pursuance of an application received on 30-10-2006.

The following entry has been made in the Register of Patents:-

CMS Peptides Patent Holdings Company Limited, a British Virgin Island Private Limited Company of Trident Chambers, P.O.Box 146, Road Town, Tortola, British Virgin Island, as proprietor by virtue of deed of Assignment dated 21st August-2006 made between **Pepharms R & D Limited**, as Assignor of the One Part and **CMS Peptides Patent Holdings Company Limited** as assignee of the Other Part.

*PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE
OF NAME IN THE REGISTER OF PATENTS.*

In the matter of Patent No. 135712 dated 10-3-1997, Granted to: - **QLT PHOTOTHERAPEUTICS, INC**, a Canadian Corporation of 520 West 6th Avenue, Vancouver, British Columbia, Canada V5Z 4H5, Canada.

In pursuance of an application received on 14-4-2005.

The following entry has been made in the Register of Patents:-

The name of the patentee has been changed to: **QLT Inc.**

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 139014 of 13-7-2004 Priority date 16-7-2003 (Germany).
Granted to: - **Boehringer Ingelheim Microparts GmbH**, incorporated under the laws
of the Federal republic of Germany, Hauert 7, 44227 Dortmund/ Germany.

In pursuance of an application received on 20-1-2007.

The following entry has been made in the Register of Patents:-

Boehringer Ingelheim Pharma GmbH & Co. KG, of Binger StraBe 173, 55216
Ingelheim am Rhein, Germany as proprietor by virtue of deed of Assignment dated
16th November, 2006 made between **Boehringer Ingelheim Microparts GmbH**, as
Assignor of the One Part and **Boehringer Ingelheim Pharma GmbH & Co. KG**, as
assignee of the Other Part.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 134616 of 01-02-1995 Granted to:- Vita-Invest, S.A., of C. Font Santa, 12-14 08970 Sant Joan Despi, Spain and later on whose name was merged into Laboratorios Vita, S.A., domiciled at Av., De Barcelona, 69, 08970 Sant Joan Despi, Barcelona, Spain and then again assigned to Vita Científica, S.L, a Spanish company, of Avenida Barcelona, 69, 08970, Sant Joan Despi, Spain.

In pursuance of an application received on 10-12-2007.

The following entry has been made in the Register of Patents:-

Inke, S.A, a Spanish company of Pol. Ind. Can Pelegri, C. Argent, 1, 08755 Castellbisbal (Barcelona), Spain as proprietor by virtue of Deed of Assignment dated 31st October, 2007 made between Vita Científica, S.L, as Assignor of the one part and Inke, S.A, as Assignee of the other parts.

**REGISTRATION OF ASSIGNMENT UNDER SECTION 55(2) RULE 37(b) OF THE PATENTS
ORDINANCE 2000**

In the matter of Patent No. 139179 of 19-01-2005 Priority date 23-10-2004 (Europe) Granted to:-
Clariant International Ltd, of Rothausstrasse 61, CH-4132 Muttenz, Switzerland.

In pursuance of an application received on 24-01-2008.

The following entry has been made in the Register of Patents:-

Clariant Finance (BVI) Limited, of Citco Building, Wickhams, Cay, P.O. Box 662, Road Town, Tortola, British Virgin Island, as Proprietor by virtue of deed of Assignment dated 5th December, 2007 made between Clariant International Ltd, as Assignor of One Part and **Clariant Finance (BVI) Limited** as Assignee of the Other Part.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-8 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139286	Pfizer Products Inc, USA	789/2001
139287	Pfizer Products Inc, USA	413/2004
139288	ENI S.p.A. and Eniteconologie S.p.A, Italy	46/2005
139289	Danisco A/S, Denmark	50/2005
139290	1.Dr. Muhammad Iqbal 2.Mr. Muhammad Younis Faisalabad, Pakistan	608/2005
130291	1.Dr. Muhammad Iqbal 2.Mr. Muhammad Younis Faisalabad, Pakistan	609/2005

(Mrs. Yasmeen Abbasi)
Controller of Patents
Tel: 9215488